Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement with fellow Chinese firm Beijing QL Biopharmaceutical Co., Ltd. concerning QL Biopharmaceutical’s glucagon-like peptide-1 (GLP-1) product, semaglutide (ZT001).
According to the terms of the agreement, Tonghua Dongbao will secure the exclusive commercialization rights for ZT001, which is intended for the control of blood glucose levels in patients with type 2 diabetes (T2D) in mainland China. The product is currently undergoing a Phase III study, having successfully completed a Phase I study in T2D patients.
Tonghua Dongbao, which launched liraglutide in China in 2023, also has two other GLP-1-related products in development: the GLP-1 receptor agonist THDBH110, which is in Phase I development for diabetes, and the GLP-1/GIP dual-targeted receptor agonist THDBH120, which is in Phase I development for diabetes and obesity.- Flcube.com
